Neuroscience

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights vodcast: 24 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week we have seen… Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights podcast: 23 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

What are the latest advancements driving neuroscience drug discovery?

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (16-20 September) 

News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 17 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week, DDW has opened registrations for its webinar ‘The latest… Read More

#News

Tau proteins
#Alzheimer's #Neurodegenerative disorders #Tau protein #University of Cambridge

New therapy targets and destroys tau tangles in Alzheimer’s

Scientists have developed two new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of neurodegeneration in mice. They say this promising approach could also be applied in future to other brain disorders driven by protein aggregation inside… Read More

#News #Trending News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights vodcast: 17 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week, DDW has opened… Read More

#News

Natural killer cells
#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More

#Editor's Choice #News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Webinar on driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

This week in drug discovery (9-13 September) 

News round-up for 9-13 September by DDW Senior Digital Content Editor Diana Spencer. This week, DDW has opened registrations for its webinar ‘The latest advancements driving neuroscience drug discovery research’, so our news highlights focus on developments in neuroscience, including a novel drug that has… Read More

#News

Neurons
#Aberdeen University #Durham University #Neurodegenerative disorders #Neuroscience #Nevrargenics #Preclinical investigations

Novel drug reduces neuronal death in neurodegenerative disease

New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. The peer reviewed study published in Frontiers in Neuroscience was conducted by academics at Aberdeen and… Read More

#News

#Automata #Automation #Collaboration #Jan and Dan Duncan Neurological Research Institute (Duncan NRI) #Neuroscience #Texas Children's Hospital

Industry/research collaboration to automate human brain studies 

The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, a neuroscience research institute based in Houston, has advanced its research capabilities with the implementation of an automation platform for human cellular model generation, maintenance, and characterisation, in collaboration with Automata Technologies.   As a global leader… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

The latest advancements driving neuroscience drug discovery

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Dementia
#Dementia #Genetics / genomics #Neurodegenerative disorders #Phase I trial #Vesper Bio

Study offers possible treatment for frontotemporal dementia

Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60. FTD(GRN), which… Read More

#Editor's Choice #News

Brain physiology
#AGuIX #Cancer research #Clinical trial #Dana-Farber Cancer Institute #Drug discovery #Neuroscience

Phase II brain metastases trial advances after futility analysis 

The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study.  The trial is being run by NH TherAguix, a biotechnology company developing… Read More

#Cancer Research #News

Neurons in the brain
#Neurocrine Biosciences #Neuroscience #Phase II trial #Psychiatry #Schizophrenia

Muscarinic M4 selective agonist shows promise in schizophrenia

Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia. NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication. The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for… Read More

#News